Prophylaxis of Radiation-Induced Nausea and Vomiting Using 5-Hydroxytryptamine-3 Serotonin Receptor Antagonists: A Systematic Review of Randomized Trials

Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases

“…The incidence, impact, and optimal management of RINV in the setting of palliative radiotherapy for bone metastases are not well described. 5-HT 3 receptor antagonists such as Ondansetron are the most commonly recommended antiemetics for the prophylaxis of RINV within practice guidelines [2,6,7] due to their superiority in preventing RINV over placebo and other antiemetics [2,8]. They are recommended as standard prophylactic treatment for moderately emetogenic radiotherapy, such as that targeting the upper abdomen, and as optional treatment for radiotherapy of lower emetogenic potential, such as that targeting the pelvis [2,6,7].…”

Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study

“…That recommendation is supported by a separate meta-analysis of nine randomized trials evaluating 5-HT 3 RAs for rinv prophylaxis, which estimated that, compared with metoclopramide and placebo, 5-HT 3 RAs provide superior control of emesis (relative risk vs. metoclopramide: 0.27; 95% confidence interval: 0.15 to 0.47; relative risk vs. placebo: 0.7; 95% confidence interval: 0.57 to 0.86) 22 . The benefit of 5-HT 3 RAs for preventing nausea was, however, less pronounced, which make our high control rates notable.…”

Side effect management during treatment of gastrointestinal (GI) cancers

“…In several studies [6][7][8] nausea was ranked as the most embarrassing symptom by GI cancer patients. Contributing parameters are the type of systemic treatment (characterized by diff erent levels of emetogenicity [9]), dose, schedule and route of administration of the drugs and individual patient characteristics [9][10][11].…”